

PHARMACY AND MEDICINES REGULATORY AUTHORITY

Confidential PMRA ACT [CHAPTER 35:01]

Form CT 8.

APPLICATION FOR AUTHORIZATION TO CONDUCT A CLINICAL TRIAL

(To be submitted in triplicate)	
l. Particulars of applicant	
If an individual: Full names	
Date and place of birth	
Qualifications	
Address (Home)	
(Business)	
If a company: Name of company	
Physical address	
Registered office	
Postal address	
Telephone number Position of person in the company who is making the application on behalf of the company	
State the main field of manufacture of the company, if applicable	
State the name of the medicine, its chemical composition, graphic and empirical formulae, animal pharmacology, toxicity and teratology as well as any clinical or field trials in humans or animals, or any other relevant information and supply reports, if any	
3. State any adverse or possible reactions to the medicine	
4. State therapeutic effects of the medicine	
 (a) Has the medicine been registered in the country of origin? YES (2) /NO (2)* If YES a valid certificate of registration in respect of such medicine issued by the appropriate authority established for the registration medicines in the country of origin shall accompany this application. 	of
If NO state details	
(b) Have clinical trials been conducted in the country of origin? YES / NO*	
If YES state details	
If NO give reasons why	
(c) Has an application for the registration of the medicine been made in any other country? YES/NO*	
If YES state details including the date on which the application was lodged	
(d) Has the medicine been registered in any other country? YES/NO*	

	If YES state details			
	(e) Has the registration	of the medicine been rejected, or refus	ed, deferred or cancelled in any country? YE	S/NO*
	If YES. state details .			
f) Wha	at is the status of the medi	cine in Malawi?		
			Tie	
			ар	propriate
1	Registered			
	_			
	Unregistered			
4	Application for registratio	n has been submitted		
	7. State the name(s), conduct the trial	, address(es) and telephone numbers) a	and qualifications of the person(s) who will	
	Name	Qualifications	Address and	Address and
			Telephone number	telephone number
			(Business)	(Homa)
			(Busiliess)	(Home)
	e the name, physical addre	ess and telephone number of the institu		ducted
 State	e the name, physical addre	ess and telephone number of the institu nd the reasons thereof	tion or the places where the trial will be cond	ducted
0. State	e the name, physical address the purpose of the trial a te the time period for the seription of the type of triandomization (e.g. methor	ess and telephone number of the institu nd the reasons thereof trial al (e.g. controlled, open) trial design (e.g. dand procedure) or any other type of	tion or the places where the trial will be cond	ducted
0. State 0. State 2. Des	e the name, physical addre	ess and telephone number of the instituend the reasons thereof trial al (e.g. controlled, open) trial design (e. od and procedure) or any other type of the controlled, open any other type of the controlled and th	tion or the places where the trial will be cond	ducted ducted diechnique (e.g. double blind, simple
	e the name, physical addre	ess and telephone number of the instituend the reasons thereof trial al (e.g. controlled, open) trial design (e. od and procedure) or any other type of esg. age group of persons or animals, types	g. parallel groups, crossover technique) blintrial	ducted ducted ducted ducted
	e the name, physical addre	ess and telephone number of the instituend the reasons thereof trial al (e.g. controlled, open) trial design (e. d) and procedure) or any other type of the est. See age group of persons or animals, types are group of participants ested to take part in the trial and a justification.	g. parallel groups, crossover technique) blin trial be or class of persons or animals, sex, etc.)	ducted ducted ducted d technique (e.g. double blind, simple
3. State 0. State 1. Declind) : 2. Des 3. Crit 4. Nui	e the name, physical addre	ess and telephone number of the instituend the reasons thereof trial al (e.g. controlled, open) trial design (e.d. and procedure) or any other type of the design of persons or animals, typession of participants cted to take part in the trial and a justification, dosage interval and period for the me	tion or the places where the trial will be cond g. parallel groups, crossover technique) blin trial be or class of persons or animals, sex, etc.) ication thereof (e.g. based on statistical consi	ducted ducted ducted d technique (e.g. double blind, simple
	e the name, physical addre	ess and telephone number of the instituend the reasons thereof trial al (e.g. controlled, open) trial design (e. dand procedure) or any other type of each of the controlled in the trial and a justification of participants cted to take part in the trial and a justification of the mean controlled in the trial and a justification of the mean controlled in the trial and a justification of the mean controlled in	g. parallel groups, crossover technique) blin trial be or class of persons or animals, sex, etc.) cication thereof (e.g. based on statistical considering tested and the medicine being u	ducted ducted ducted diechnique (e.g. double blind, simple
	e the name, physical addre	ess and telephone number of the instituend the reasons thereof trial al (e.g. controlled, open) trial design (e.d. and procedure) or any other type of each of the controlled of the controlle	g. parallel groups, crossover technique) blin trial be or class of persons or animals, sex, etc.) cication thereof (e.g. based on statistical consideration dicine being tested and the medicine being u	ducted ducted ducted diechnique (e.g. double blind, simple

(b) State whether a person already on another medicine will be given the experimental medicine at the same time or whether the participant will be taken off the other medicine.

18. Recording of effects	give a description of the methods	of recordings and times of recordi	ings
19. State clinical and lab	poratory tests, pharmacokinetic an	nalysis, etc., that are to be carried or	ut
20. State the method of	recording adverse reactions and p	provisions for dealing with same an	d other complications
21. State antidote			
22. State the procedure	for the keeping of participant lists	and participant records for each p	articipant taking part in the trial +
23. State where the tria	l code will be kept and how it can b	pe broken in the event of an emerg	ency
24. State the measures to instructions	to be implemented to ensure the sa	afe handling of medicines and to pr	romote and control compliances with the prescribed
25. Evaluation of result:	s, state the description of methodo	ology (e.g. statistical methods)	
26. State how the perso	ns or owners of animals are to be i	informed about the trial	
	involved are to be informed about at to do in an emergency	the way the trial is to be conducted	d and about the procedures for medicine usage and
28. State whether there		ations relating to the trial, giving de	
29. State the name and	address of the company who will in	nsure all the participants in the pro	oposed trial ++
	insurance in respect of each partic	cipant	
		n is required if the medicine is not	
32. Particulars of perso	ns who will take part in the clinical	l trial+++	
Name 1	Occupation	Address	Date and place of birth
2			
	imals that will take part in the clin	ical trial.	
Kind and breed o	of animal		

	wnof owners of animals.	·······
Name	Address	
1		
2		
34. Attached is a sample	of the medicine, together with methods of analysis and storage conditions.	
Date		
	Signature of applicant	
Countersignature of medica	superintendent or senior medical officer if the clinical trial is to be conducted in a hospital or a medical	institution. ++++
Date		
Notes		
*Delete the inapplicable		
participants.	ld permit easy identification of individual	
the propose insu +++, item 31: The	letter from the insurance company shall be attached to the application indicating the insurance compar rance and a copy of the proposed insurance policy. consent of each person or the guardian of such person who will participate in the trial is required to be	y's consent to
Γhe consent of each owner of	lication Form M.C. 17. f an animal which will participate in the trial is required to be attached to the application, this item a veterinary surgeon if the trial is to be conducted in a veterinary hospital.	
	FOR OFFICIAL USE ONLY	
1 Clinical Trial Review	Committee's comments on the application	
2. Application approve	l/disapproved by the Acting Director General.	
Comments		,
Date		
	Director General PMRA	